April 3, 2018 / 5:11 AM / 20 days ago

BRIEF-Argenx ‍To Present Complete Data From Phase 2 Clinical Trial Of Efgartigimod

Reuters Staff

1 Min Read

April 3 (Reuters) - ARGENX NV:

* ‍TO PRESENT COMPLETE DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD (ARGX-113) IN MYASTHENIA GRAVIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.